

HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing

- I. Minimal residual disease (MRD) analysis for HPV-related head and neck cancers using cell-free DNA is **medically necessary** when:
 - A. The member has a personal history of HPV-driven oropharyngeal cancer, **AND**
 - B. The identification of recurrence or progression of disease will require a change in management, **AND**
 - C. The member is not undergoing concurrent surveillance or monitoring for recurrence or progression by any other method, **AND**
 - D. The member meets one of the following:
 1. The member is currently being treated for HPV-driven oropharyngeal cancer, **AND**
 - a) The test has not previously been done for this episode of cancer, **OR**
 2. The member is not currently being treated for HPV-driven oropharyngeal cancer, **AND**
 - a) The test has not been done in the past 12 months.
- II. Minimal residual disease (MRD) analysis for HPV-related head and neck cancers using cell-free DNA is considered **investigational** for all other indications.

REFERENCES

1. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Local Coverage Determination. MoIDX: Minimal Residual Disease Testing for Cancer (L38779). Available at:
<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38779>
2. Centers for Medicare & Medicaid Services. Medicare Coverage Database: Billing and Coding: MoIDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58376). Available at:
<https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=58376>